Kristian Strømgaard was visiting professor at Harvard Medical School (Boston) to explore medical research and innovation. In 2021 he was awarded the University of Copenhagen Innovation Award and appointed Novo Nordisk Foundation Distinguished Innovator. In 2023 he was awarded the Danish Academy of Natural Sciences Industrial Prize. In 2012, he co-founded Avilex Pharma, and as CEO/CSO he drove the lead compound successfully through Phase 1 clinical studies and secured a regional license deal worth $175M. He has filed 19 patent applications, several of which have been outlicensed and provided the foundation for three start-up companies (incl. Avilex Pharma). He is currently leading Neurophase, a Biostudio (3-year spin-out) program at the BioInnovation Institute.